Antibodies and peptides in cancer therapy

Area of Science:

• Oncology
• Immunotherapy
• Drug Development

Background:

• Antibodies and peptides are vital in cancer treatment.
• Monoclonal antibodies (mAbs) and peptides serve as direct anticancer therapies and targeting moieties.
• Over 10 mAbs are approved for oncological use, in unconjugated or immunoconjugate forms.

Purpose of the Study:

• To review the significant applications of antibodies and peptides in cancer therapy.
• To highlight their dual role as direct therapeutic agents and targeting tools.
• To summarize advancements in peptide identification for cancer targeting.

Main Methods:

• Literature review of antibody and peptide applications in cancer therapy.
• Analysis of approved monoclonal antibodies in oncology.
• Summary of peptide identification techniques, including phage-display libraries.
• Evaluation of combination therapies involving mAbs, peptides, and chemotherapy.

Main Results:

• Monoclonal antibodies (mAbs) and peptides are established in cancer treatment.
• Phage-display libraries have identified various peptides, including tumor necrosis factors (TNFs) and cell surface-targeted peptides.
• Combination therapy with mAbs and peptides enhances anticancer drug efficacy against tumors.
• These combinations also reduce adverse side effects on normal tissues.

Conclusions:

• Antibodies and peptides are versatile tools in modern cancer therapy.
• Their strategic use improves treatment outcomes and patient safety.
• Further research into antibody and peptide applications promises continued advancements in oncology.